Xenon Pharmaceuticals (XENE) Long-Term Investments (2022 - 2026)

Xenon Pharmaceuticals (XENE) has 5 years of Long-Term Investments data on file, last reported at $244.9 million in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 73.06% year-over-year to $244.9 million in Q1 2026; TTM through Mar 2026 was $244.9 million, a 73.06% increase from a year earlier, with the FY2025 full-year figure at $37.2 million, down 70.86% from the prior year.
• Long-Term Investments for Q1 2026 stood at $244.9 million, up from $37.2 million in the prior quarter.
• Over the last five years, Long-Term Investments for XENE reached as high as $292.8 million in Q4 2023 and fell as low as $37.2 million in Q4 2025.
• Historically, Long-Term Investments has averaged $144.4 million across 5 years, with a median of $129.1 million in 2024.
• Across the five-year window, Long-Term Investments soared 127.53% in 2023 and slumped 70.86% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $128.7 million in 2022, then surged by 127.53% to $292.8 million in 2023, then sank by 56.46% to $127.5 million in 2024, then slumped by 70.86% to $37.2 million in 2025, then jumped by 559.11% to $244.9 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $244.9 million in Q1 2026, $37.2 million in Q4 2025, and $93.0 million in Q3 2025.